BRPI0707645B8 - métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano - Google Patents

métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano

Info

Publication number
BRPI0707645B8
BRPI0707645B8 BRPI0707645A BRPI0707645A BRPI0707645B8 BR PI0707645 B8 BRPI0707645 B8 BR PI0707645B8 BR PI0707645 A BRPI0707645 A BR PI0707645A BR PI0707645 A BRPI0707645 A BR PI0707645A BR PI0707645 B8 BRPI0707645 B8 BR PI0707645B8
Authority
BR
Brazil
Prior art keywords
individual
bcl
cancer
prognosis
suspected
Prior art date
Application number
BRPI0707645A
Other languages
English (en)
Inventor
A Kruk Patricia
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of BRPI0707645A2 publication Critical patent/BRPI0707645A2/pt
Publication of BRPI0707645B1 publication Critical patent/BRPI0707645B1/pt
Publication of BRPI0707645B8 publication Critical patent/BRPI0707645B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

detecção de câncer por níveis elevados de bcl-2. a presente invenção refere-se a um método para o diagnóstico, prognóstico e monitoração de câncer, tal como câncer ovariano de estágio precoce ou tardio, em um indivíduo por de-tecção de bcl-2 em uma amostra biológica a partir do indivíduo, de preferência uma amostra de urina ou de sangue. bcl-2 pode ser medido usando-se um agente que detecta ou se liga à proteína de bcl-2 ou a um agente que detecta ou se liga a ácidos nucléicos de codificação, tais anticorpos especificamente reativos com proteína de bcl-2 ou uma sua porção. a inven-ção ulteriormente refere-se a kits para a realização dos métodos da invenção. a invenção ulteriormente refere-se a um dispositivo para a detecção rápida de bcl-2 em um fluido corpó-reo e métodos para rapidamente medir bci-2 em um fluido corpóreo.
BRPI0707645A 2006-02-09 2007-02-09 métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano BRPI0707645B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77167706P 2006-02-09 2006-02-09
US60/771,677 2006-02-09
PCT/US2007/003608 WO2007092627A2 (en) 2006-02-09 2007-02-09 Detection of cancer by elevated levels of bcl-2

Publications (3)

Publication Number Publication Date
BRPI0707645A2 BRPI0707645A2 (pt) 2011-05-10
BRPI0707645B1 BRPI0707645B1 (pt) 2019-04-09
BRPI0707645B8 true BRPI0707645B8 (pt) 2021-07-27

Family

ID=38345845

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707645A BRPI0707645B8 (pt) 2006-02-09 2007-02-09 métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano

Country Status (16)

Country Link
US (4) US8034549B2 (pt)
EP (1) EP1996940B1 (pt)
JP (1) JP4896994B2 (pt)
KR (1) KR20080114689A (pt)
CN (1) CN101384903A (pt)
AT (1) ATE538386T1 (pt)
AU (1) AU2007212278A1 (pt)
BR (1) BRPI0707645B8 (pt)
CA (1) CA2642051C (pt)
IL (1) IL192866A (pt)
NO (1) NO20083820L (pt)
NZ (1) NZ570008A (pt)
RU (1) RU2436098C2 (pt)
SG (1) SG169395A1 (pt)
WO (1) WO2007092627A2 (pt)
ZA (1) ZA200805787B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022414A1 (en) * 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
US20060078893A1 (en) * 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP1984738A2 (en) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
CN101384903A (zh) 2006-02-09 2009-03-11 南佛罗里达大学 利用bcl-2水平的增高检测癌肿
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP4190448A3 (en) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Microfluidic devices
CN103424541B (zh) * 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20100256610A1 (en) * 2007-10-25 2010-10-07 Basil Rigas Apparatus and method of detection and localized treatment of abnormal conditions
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010042225A2 (en) * 2008-10-10 2010-04-15 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
WO2010115196A1 (en) * 2009-04-03 2010-10-07 Candela Corporation Skin resurfacing at 1930 nm
IN2012DN00707A (pt) * 2009-07-24 2015-06-19 Geadic Biotec Aie
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
US20160186266A1 (en) * 2009-10-27 2016-06-30 Carislife Sciences, Inc. Molecular profiling for personalized medicine
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP4435111A1 (en) 2010-02-12 2024-09-25 Bio-Rad Laboratories, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012061759A2 (en) * 2010-11-05 2012-05-10 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
WO2012116229A2 (en) * 2011-02-23 2012-08-30 Mdsure Ltd Compositions and methods for personal tumor profiling treatment
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2013009690A2 (en) 2011-07-09 2013-01-17 The Regents Of The University Of California Leukemia stem cell targeting ligands and methods of use
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013035095A1 (en) * 2011-09-08 2013-03-14 Ben-Gurion University Of The Negev Research And Development Authority Methods for diagnosing cancer
EP2758777B1 (en) * 2011-09-22 2018-02-07 Memorial Sloan-Kettering Cancer Center Detecting ovarian cancer
CA2853103C (en) * 2011-10-21 2020-01-07 Decimadx, Llc Point-of-care immunoassay for quantitative small analyte detection
EP2823303A4 (en) 2012-02-10 2015-09-30 Raindance Technologies Inc MOLECULAR DIAGNOSTIC SCREENING TEST
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
ES2685580T3 (es) 2013-08-19 2018-10-10 Biontech Diagnostics Gmbh Métodos y kits para la subtipificación molecular de tumores
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
US11060149B2 (en) 2014-06-18 2021-07-13 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
US9810610B2 (en) 2014-09-17 2017-11-07 Hologic, Inc. Method of partial lysis and assay
GB201417281D0 (en) * 2014-09-30 2014-11-12 Ge Healthcare Uk Ltd Methods and devices relating to the detection of oral cancer biomarkers
JP5995117B2 (ja) * 2015-01-26 2016-09-21 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
US12275994B2 (en) 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3817756A4 (en) * 2018-07-05 2022-03-30 Ovation Diagnostics LLC BCL-2 ANTIBODIES AND IMMUNOASSAY FOR CANCER DIAGNOSIS
CN109374897B (zh) * 2018-11-22 2021-11-02 大连大学 一种用于肝癌检测的试剂盒
AU2020398476A1 (en) * 2019-12-06 2022-07-14 Proteina, Co., Ltd. Method for predicting reactivity to drug targeting BCL2 family protein
EP4138845A4 (en) * 2020-04-21 2024-10-09 Carlo M. Croce METHODS FOR DETECTING AND TREATING CANCER WITH LOSS OF MIR15 AND MIR16 EXPRESSION
IL298134A (en) * 2020-05-12 2023-01-01 Lonza Houston Inc Methods and kits for the detection of adeno-associated viruses
CN111679076A (zh) * 2020-06-15 2020-09-18 吉林医药学院 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒
WO2023239572A1 (en) * 2022-06-01 2023-12-14 Northeastern University Enhanced specificity mass tag dna adductomics
WO2025075824A1 (en) * 2023-10-02 2025-04-10 Siemens Healthcare Diagnostics Inc. Urine sediment interface with probabilistic classification binning and methods of producing and using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4260678A (en) 1979-02-23 1981-04-07 Corning Glass Works Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes
US4381291A (en) 1979-02-23 1983-04-26 Ab Fortia Measurement of free ligands
US4343312A (en) 1979-04-16 1982-08-10 Vitafin N.V. Pacemaker output circuit
FR2455743A1 (fr) 1979-05-02 1980-11-28 Goella Laboratoires Procede et dispositif pour le dosage des lipoproteines seriques
US4357311A (en) 1980-10-03 1982-11-02 Warner-Lambert Company Substrate for immunoassay and means of preparing same
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
JPS59500735A (ja) 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4617261A (en) 1984-03-21 1986-10-14 Cetus Corporation Process for labeling nucleic acids and hybridization probes
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5356817A (en) 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
US5312922A (en) 1992-04-06 1994-05-17 Nordion International Inc. Europium and terbium chelators for time-resolved fluorometric assays
EP0689673B1 (en) * 1993-03-17 1997-07-02 Akzo Nobel N.V. Apparatus for the detection of a specifically reacting substance
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US6811995B1 (en) 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
DE19936618A1 (de) * 1999-08-04 2001-03-15 Monotec Gmbh Diagnostisches Kit und dessen Verwendung
EP1257560A4 (en) 2000-02-01 2003-10-01 Human Genome Sciences Inc BCL-2 SIMILAR POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES
KR100414637B1 (ko) * 2000-02-08 2004-01-13 (주)에스제이바이오메드 사람 미토콘드리아 아데닐레이트 키나제 이소자임들에대한 항체와 면역학적 제제 및 심장질환 진단키트
US7279294B2 (en) 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US6492127B2 (en) * 2001-01-23 2002-12-10 Varian, Inc. Lateral flow testing device with on-board chemical reactant
AU2002309668A1 (en) 2001-05-07 2002-11-18 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
CA2446825A1 (en) * 2001-05-07 2002-11-14 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
KR20030092378A (ko) * 2002-05-29 2003-12-06 박영미 고형암의 진행 정도를 진단하는 방법 및 키트
WO2003105899A1 (en) * 2002-06-13 2003-12-24 Neuropro Technologies, Inc. Apparatus and methods for detecting cerebrospinal fluid
CN1402004A (zh) * 2002-09-27 2003-03-12 江西中德生物工程有限公司 一种免疫层析一步法检测β－肾上腺素激动剂类药物的方法及试纸的制备
US20040137538A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive assay kit for identifying cancer protein patterns
US7288383B2 (en) 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
US20060078986A1 (en) * 2004-09-30 2006-04-13 Quidel Corporation Analytical devices with primary and secondary flow paths
CN101384903A (zh) 2006-02-09 2009-03-11 南佛罗里达大学 利用bcl-2水平的增高检测癌肿

Also Published As

Publication number Publication date
SG169395A1 (en) 2011-03-30
JP4896994B2 (ja) 2012-03-14
US20160258960A1 (en) 2016-09-08
AU2007212278A1 (en) 2007-08-16
EP1996940A2 (en) 2008-12-03
BRPI0707645B1 (pt) 2019-04-09
NZ570008A (en) 2011-10-28
ZA200805787B (en) 2009-05-27
EP1996940A4 (en) 2009-10-21
WO2007092627A9 (en) 2007-10-18
ATE538386T1 (de) 2012-01-15
WO2007092627A2 (en) 2007-08-16
CA2642051C (en) 2017-01-24
JP2009526234A (ja) 2009-07-16
KR20080114689A (ko) 2008-12-31
EP1996940B1 (en) 2011-12-21
BRPI0707645A2 (pt) 2011-05-10
IL192866A (en) 2013-04-30
US8034549B2 (en) 2011-10-11
RU2008136193A (ru) 2010-03-20
US20190072556A1 (en) 2019-03-07
US11156613B2 (en) 2021-10-26
CN101384903A (zh) 2009-03-11
RU2436098C2 (ru) 2011-12-10
CA2642051A1 (en) 2007-08-16
WO2007092627A3 (en) 2008-11-13
US20080009005A1 (en) 2008-01-10
NO20083820L (no) 2008-11-07
US20110318763A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
NO20076656L (no) Forbedrede immunoassay metoder
WO2008021290A8 (en) Organ-specific proteins and methods of their use
ATE438853T1 (de) Diagnostische testvorrichtung
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
BR112012029520A2 (pt) instrumento de diagnóstico e processo de fluxo.
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
DE602006021777D1 (de) Diagnoseverfahren für präeklampsie
Chen et al. A dual-aptamer sandwich assay by detection of C-reactive protein in synovial fluid on an integrated microfluidic system for diagnosis of periprosthetic joint infection
RU2008103988A (ru) Способ диагностики рассеяного склероза
CY1109461T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
BRPI0515317A (pt) sistema e método para reposicionar uma fita de teste para diagnóstico depois da inoculação
EP2444812A3 (en) Improved immunoassay methods
BRPI0618435A2 (pt) composição reagente de sensor teste tendo polìmeros de celulose adaptada para auxiliar na determinação de uma concentração de analito de uma amostra fluida, bem como processo de determinação de uma concentração de analito de uma amostra fluida
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
WO2014159920A4 (en) A device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers
ATE509270T1 (de) Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung
TW200720657A (en) Diagnosis method of endometriosis by detecting biochemical markers and usage of these biochemical markers
PL446010A1 (pl) Sposób wykrywania materiału genetycznego wirusa SARS-CoV-2, sposób diagnozowania in vitro zakażenia wirusem SARS-CoV-2 w wersji laboratoryjnej i zestaw testowy
CY1115323T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
AR066491A1 (es) Equipo de enzimoinmunoensayo ( elisa) para el diagnostico de leptospirosis humana
Etreby et al. Fibrosis 4 score versus hyaluronic acid as non-invasive tools for assessment of Hcv-related hepatic fibrosis: correlation with quantitative morphometric analysis of liver biopsy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.